Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05257967 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2026v5
  2. 2 versions Re-verified since Jul 26, 2023, no change to tracked fieldsv3-v4
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 1, 2022 to Jul 18, 2022 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 1, 2022 to Jul 18, 2022
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life. With improvement in treatment options, rates of leptomeningeal disease are increasing and currently found in up to 9% of EGFR mutant NSCLC. Systemic therapy may be more effective if it can target the correct molecular aberration. The molecular characterization of central nervous system disease may differ from disease outside of the central nervous system. The aim of this pilot trial is to evaluate for molecular differences between cerebral spinal fluid (CSF) and blood circulating tumor DNA (ctDNA) through the use of ddPCR and BC Cancer NGS panel molecular testing.
Trial Details
NCT Number NCT05257967
Lead Sponsor British Columbia Cancer Agency
Conditions EGFR Activating Mutation, Leptomeningeal Metastasis, Non Small Cell Lung Cancer
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov